HER2 overexpression, which arises from the amplification of the ERBB2/neu proto‐oncogene located on the centromere of chromosome 17 (CEN17), is found in approximately 15%–20% of breast cancers.3 This evidence concerns the gene ERBB2 and breast cancer.